semaglutide cease and desist The Food Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included “false or misleading” claims about the medicine's abilities and benefits to patients. In December 7, 2025: FDA seized

Research indicates BPC-157 significantly enhances cell survival under oxidative stress conditions (H2O2 exposure), protecting fibroblasts during the inflammatory phase of healing when reactive oxygen species are elevated

Key results: 12 mg dose: Average weight loss of 24.2 percent of body weight 8 mg dose: Average weight loss of 22.8 percent 4 mg dose: Average weight loss of 17.0 percent Over 90 percent of participants at 8 or 12 mg lost at least 10 percent of body weight Over 75 percent at 12 mg lost at least 20 percent Crucially, the weight loss curve had not yet plateaued at 48 weeks, suggesting longer treatment may produce even greater results

Its primary activity is CNS-based

4 Heart and Stroke Richard Lewar Center of Excellence in Cardiovascular Research, and 5 Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada